Better Therapeutics BTTX Stock
Better Therapeutics Price Chart
Better Therapeutics BTTX Financial and Trading Overview
| Better Therapeutics stock price | 0.01 USD |
| Previous Close | 0.87 USD |
| Open | 0.9 USD |
| Bid | 0 USD x 1300 |
| Ask | 0 USD x 2900 |
| Day's Range | 0.87 - 0.99 USD |
| 52 Week Range | 0.59 - 2.8 USD |
| Volume | 165.62K USD |
| Avg. Volume | 162.9K USD |
| Market Cap | 31.09M USD |
| Beta (5Y Monthly) | 1.571743 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7 USD |
BTTX Valuation Measures
| Enterprise Value | 36.14M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.8304238 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.959 |
Trading Information
Better Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.571743 |
| 52-Week Change | -35.52% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.8 USD |
| 52 Week Low | 0.59 USD |
| 50-Day Moving Average | 0.98 USD |
| 200-Day Moving Average | 1.29 USD |
BTTX Share Statistics
| Avg. Volume (3 month) | 162.9K USD |
| Avg. Daily Volume (10-Days) | 150.87K USD |
| Shares Outstanding | 31.73M |
| Float | 10.31M |
| Short Ratio | 0.46 |
| % Held by Insiders | 56.04% |
| % Held by Institutions | 4.94% |
| Shares Short | 88.76K |
| Short % of Float | 0.85% |
| Short % of Shares Outstanding | 0.27% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -89.084% |
| Return on Equity (ttm) | -448.55% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -37697000 USD |
| Net Income Avi to Common (ttm) | -39455000 USD |
| Diluted EPS (ttm) | -1.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.07M USD |
| Total Cash Per Share (mrq) | 0.19 USD |
| Total Debt (mrq) | 14.54M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.619 |
| Book Value Per Share (mrq) | -0.412 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28791000 USD |
| Levered Free Cash Flow (ttm) | -15644375 USD |
Profile of Better Therapeutics
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 548 Market Street |
| ZIP | 94104 |
| Phone | 415 887 2311 |
| Website | https://www.bettertx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 54 |
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Q&A For Better Therapeutics Stock
What is a current BTTX stock price?
Better Therapeutics BTTX stock price today per share is 0.01 USD.
How to purchase Better Therapeutics stock?
You can buy BTTX shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Better Therapeutics?
The stock symbol or ticker of Better Therapeutics is BTTX.
Which industry does the Better Therapeutics company belong to?
The Better Therapeutics industry is Biotechnology.
How many shares does Better Therapeutics have in circulation?
The max supply of Better Therapeutics shares is 54.52M.
What is Better Therapeutics Price to Earnings Ratio (PE Ratio)?
Better Therapeutics PE Ratio is now.
What was Better Therapeutics earnings per share over the trailing 12 months (TTM)?
Better Therapeutics EPS is -1.1 USD over the trailing 12 months.
Which sector does the Better Therapeutics company belong to?
The Better Therapeutics sector is Healthcare.
Better Therapeutics BTTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}